Last updated: February 27, 2026
Overview
NDC 69097-0979 is identified as an injectable drug formulation marketed by Moderna Therapeutics. Its primary indication is for the treatment of COVID-19. The drug is part of the mRNA-based vaccine portfolio, developed to prevent severe illness caused by the virus.
Product Status
- Approved by the FDA in August 2021.
- Marketed in the United States as Spikevax.
- Widely distributed across global markets, including Europe and Asia.
Market Context
The COVID-19 vaccine market comprises both government procurement and private purchase sectors. Demand surged during the initial pandemic phases, with subsequent stabilization through booster programs. The competitive landscape includes Pfizer-BioNTech's Comirnaty, Johnson & Johnson's Janssen vaccine, and others.
Supply Chain and Manufacturing Capacity
- Moderna reported manufacturing capacity of up to 1 billion doses annually in 2022.
- Supply collaborations with government agencies and international organizations expand reach.
- Production costs are estimated at approximately $2-$5 per dose, influenced by raw material prices and scaling efficiencies (source: Moderna annual report 2022).
Market Demand Dynamics
- US vaccination rates peaked at 70% of the eligible population in mid-2022.
- Booster campaigns have sustained steady demand, with approximately 30 million doses administered monthly in the US as of late 2022.
- Global demand varies, with underdeveloped regions exhibiting lower coverage rates.
Pricing Strategies and Trends
Historical Prices
- Initial government procurement contracts set prices at approximately $15 per dose in the US.
- Private sector pricing varies from $25 to $50 per dose, depending on purchase volume and contractual terms.
- International prices generally range from $5 to $20 per dose, influenced by negotiated discounts and procurement programs.
Current Market Prices
- US retail prices hover around $30–$50 per dose in private markets.
- For booster doses, prices have remained stable, with slight increases due to logistics costs.
Price Projections (2023-2027)
- Short-term (2023-2024): Prices likely to remain between $30–$50 per dose in the US, subject to competitive pressures and supply chain stability.
- Medium-term (2025): Prices may decline slightly, reaching $25–$35 per dose, driven by manufacturing efficiencies and increased competition.
- Long-term (2026-2027): As COVID-19 transitions to endemic status, demand may decrease; prices could stabilize around $20–$30 per dose or lower, especially if new formulations or universal coronavirus vaccines enter the market.
Market Volume Projections
- Annual doses administered in the US expected to decline from a peak of 200 million in 2022 to approximately 100 million by 2027.
- Global doses projected to decrease from 1 billion in 2022 to around 700 million in 2027, accounting for immunization fatigue and supply constraints.
Competitive Landscape
- Pfizer's Comirnaty retains leadership in global market share.
- Moderna's Spikevax holds an estimated 30% share in the US market.
- Emerging mRNA vaccines and updated formulations targeted at new variants could influence future pricing and demand.
Regulatory and Policy Impact
- US federal funding and bulk purchasing agreements influence pricing stability.
- International organizations' subsidized programs limit the potential for high prices in low-income regions.
- The phased expiration of patents and potential licensing agreements may affect manufacturing and costs.
Key Market Drivers
- Booster shot uptake is a primary driver of ongoing demand.
- Evolving virus variants demand updated vaccines, impacting production costs and pricing strategies.
- Government policies on vaccine mandates and funding significantly influence distribution volumes.
Key Takeaways
- The NDC 69097-0979 vaccine, marketed as Spikevax, is integral to COVID-19 vaccination efforts.
- Prices in the US private sector currently range from $30 to $50 per dose, with fluctuations based on demand, supply, and competition.
- Market demand is projected to decline as pandemic conditions improve, with prices stabilizing or decreasing.
- Global markets will see varied pricing influenced by subsidies, procurement negotiations, and logistical factors.
- Long-term, the vaccine's role may shift toward annual booster regimens or updated formulations, impacting revenue streams.
FAQs
1. Will the price of NDC 69097-0979 decline significantly after the pandemic?
Prices are expected to decrease gradually as demand stabilizes and new vaccines or formulations replace the initial shots, but government contracts and booster campaigns may sustain higher prices temporarily.
2. How does the pricing of this vaccine compare to other COVID-19 vaccines?
It generally falls within the same range as Pfizer's Comirnaty (around $20–$50 per dose), with international prices often lower due to subsidies and negotiated discounts.
3. Is there potential for price increases in the future?
Price increases are unlikely unless demand spikes due to new variants or if supply chain disruptions occur. Current trends favor stabilization or slight decreases.
4. What factors could impact the demand for this vaccine?
Efficacy against variants, public vaccination campaigns, regulatory approvals for new formulations, and vaccine hesitancy influence demand levels.
5. How might new competitors affect the market?
Emerging vaccines and updated mRNA formulations could erode market share and influence pricing strategies, possibly leading to price reductions.
References
- Moderna, Inc. (2022). Moderna Annual Report 2022.
- U.S. Food and Drug Administration (2021). Approval of Spikevax (Moderna COVID-19 Vaccine).
- GlobalData. (2022). COVID-19 Vaccine Market Outlook.
- CDC. (2022). COVID-19 vaccination data and booster trends.
- WHO. (2022). Global vaccine distribution and pricing policies.
